The effect of COVID-19 on patients recieving omalizumab treatment

BACKGROUND AND AIM: Although exposure during drug administration and susceptibility to coronavirus disease-19 (COVID-19) infection secondary to immunomodulatory effects constitute potential risks for patients with chronic spontaneous urticaria (CSU) or asthma on omalizumab (OMZ), there is a risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayaca, N., Cansız, K.A., Yıldırım, E., Öztürk, B., Kırmaz, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812821/
https://www.ncbi.nlm.nih.gov/pubmed/36624750
http://dx.doi.org/10.1016/j.reval.2023.103281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812821/
https://www.ncbi.nlm.nih.gov/pubmed/36624750
http://dx.doi.org/10.1016/j.reval.2023.103281

Ejemplares similares